These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22440215)

  • 1. Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1.
    Shao Z; Wang Z; Shrestha K; Thakur A; Borowski AG; Sweet W; Thomas JD; Moravec CS; Hazen SL; Tang WH
    J Am Coll Cardiol; 2012 Mar; 59(13):1150-8. PubMed ID: 22440215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure.
    Tang WH; Tong W; Shrestha K; Wang Z; Levison BS; Delfraino B; Hu B; Troughton RW; Klein AL; Hazen SL
    Eur Heart J; 2008 Oct; 29(20):2506-13. PubMed ID: 18687662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of asymmetric dimethylarginine (ADMA) on heart failure development.
    Liu X; Hou L; Xu D; Chen A; Yang L; Zhuang Y; Xu Y; Fassett JT; Chen Y
    Nitric Oxide; 2016 Apr; 54():73-81. PubMed ID: 26923818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis.
    Chandrasekharan UM; Wang Z; Wu Y; Wilson Tang WH; Hazen SL; Wang S; Elaine Husni M
    Arthritis Res Ther; 2018 Jun; 20(1):123. PubMed ID: 29884228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase.
    Achan V; Broadhead M; Malaki M; Whitley G; Leiper J; MacAllister R; Vallance P
    Arterioscler Thromb Vasc Biol; 2003 Aug; 23(8):1455-9. PubMed ID: 12805079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased symmetrical dimethylarginine in ischemic acute kidney injury as a causative factor of renal L-arginine deficiency.
    Betz B; Möller-Ehrlich K; Kress T; Kniepert J; Schwedhelm E; Böger RH; Wanner C; Sauvant C; Schneider R
    Transl Res; 2013 Aug; 162(2):67-76. PubMed ID: 23707198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased exhaled nitric oxide levels after exercise in patients with chronic systolic heart failure with pulmonary venous hypertension.
    Schuster A; Thakur A; Wang Z; Borowski AG; Thomas JD; Tang WH
    J Card Fail; 2012 Oct; 18(10):799-803. PubMed ID: 23040116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk.
    Tang WH; Wang Z; Cho L; Brennan DM; Hazen SL
    J Am Coll Cardiol; 2009 Jun; 53(22):2061-7. PubMed ID: 19477356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential treatment influences and mechanisms related to asymmetric dimethylarginine control in heart failure.
    Billecke SS; D'Alecy LG; Marcovitz PA
    J Am Coll Cardiol; 2012 Sep; 60(10):948-9; author reply 949. PubMed ID: 22935469
    [No Abstract]   [Full Text] [Related]  

  • 10. The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature.
    Visser M; Paulus WJ; Vermeulen MA; Richir MC; Davids M; Wisselink W; de Mol BA; van Leeuwen PA
    Eur J Heart Fail; 2010 Dec; 12(12):1274-81. PubMed ID: 20923854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension.
    Millatt LJ; Whitley GS; Li D; Leiper JM; Siragy HM; Carey RM; Johns RA
    Circulation; 2003 Sep; 108(12):1493-8. PubMed ID: 12952847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age-related changes in ADMA-DDAH-NO pathway in rat liver subjected to partial ischemia followed by global reperfusion.
    Trocha M; Merwid-Ląd A; Chlebda-Sieragowska E; Szuba A; Pieśniewska M; Fereniec-Gołębiewska L; Kwiatkowska J; Szeląg A; Sozański T
    Exp Gerontol; 2014 Feb; 50():45-51. PubMed ID: 24269305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction.
    Nicholls SJ; Wang Z; Koeth R; Levison B; DelFraino B; Dzavik V; Griffith OW; Hathaway D; Panza JA; Nissen SE; Hochman JS; Hazen SL
    Circulation; 2007 Nov; 116(20):2315-24. PubMed ID: 17967979
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Chronic Intermittent Hypobaric Hypoxia in Rats Causes an Imbalance in the Asymmetric Dimethylarginine/Nitric Oxide Pathway and ROS Activity: A Possible Synergistic Mechanism for Altitude Pulmonary Hypertension?
    Lüneburg N; Siques P; Brito J; Arriaza K; Pena E; Klose H; Leon-Velarde F; Böger RH
    Pulm Med; 2016; 2016():6578578. PubMed ID: 27313889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease.
    Liu X; Xu X; Shang R; Chen Y
    Nitric Oxide; 2018 Aug; 78():113-120. PubMed ID: 29928990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of asymmetric dimethylarginine and Rho kinase in the vascular remodeling in monocrotaline-induced pulmonary hypertension.
    Li XH; Peng J; Tan N; Wu WH; Li TT; Shi RZ; Li YJ
    Vascul Pharmacol; 2010; 53(5-6):223-9. PubMed ID: 20840872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine.
    Hu X; Atzler D; Xu X; Zhang P; Guo H; Lu Z; Fassett J; Schwedhelm E; Böger RH; Bache RJ; Chen Y
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1540-6. PubMed ID: 21493890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Asymmetric dimethylarginine and critical illness.
    Brinkmann SJ; de Boer MC; Buijs N; van Leeuwen PA
    Curr Opin Clin Nutr Metab Care; 2014 Jan; 17(1):90-7. PubMed ID: 24281375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired flow-mediated dilation with age is not explained by L-arginine bioavailability or endothelial asymmetric dimethylarginine protein expression.
    Gates PE; Boucher ML; Silver AE; Monahan KD; Seals DR
    J Appl Physiol (1985); 2007 Jan; 102(1):63-71. PubMed ID: 16946027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of dimethylarginine dimethylaminohydrolase activity in regulation of tissue and plasma concentrations of asymmetric dimethylarginine in an animal model of prolonged critical illness.
    Davids M; Richir MC; Visser M; Ellger B; van den Berghe G; van Leeuwen PA; Teerlink T
    Metabolism; 2012 Apr; 61(4):482-90. PubMed ID: 22000584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.